NCT03116295View on ClinicalTrials.gov

Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

June 20, 2017

Primary Completion Date

August 28, 2017

Study Completion Date

August 28, 2017

Conditions
Parkinson Disease
Interventions
DRUG

Opicapone (OPC)

Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors
lead

Bial - Portela C S.A.

INDUSTRY

NCT03116295 - Bioavailability and Bioequivalence Study of Two Different Sources of Opicapone | Biotech Hunter | Biotech Hunter